Dr. Sandip Shah appointed as Chairperson of NABL-QCI

Cipla launches India's first inhalable insulin ‘Afrezza’

Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management

SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP

SPARC to receive 55% equity in Tiller Therapeutics

Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'

A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%

Biocon Biologics recognized as Asia IP Elite for 2024 by IAM

Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list

Lupin gets tentative approval from USFDA for Sitagliptin and Metformin Hydrochloride Tablets

Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dr. Reddy's launches Toripalimab in India

The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions

India embraces AI and Virtual Care to bridge workforce gaps in healthcare: Philips Future Health Index India 2024

USFDA accepts Blenrep combinations for treatment of relapsed/refractory multiple myeloma

If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse